Skip to main content
. 2021 Nov 8;16(11):e0258319. doi: 10.1371/journal.pone.0258319

Fig 3. Cumulative survival (days) in the Brazilian aHUS cohort patients divided by groups: Not received eculizumab (red), prophylactic eculizumab (green), and eculizumab treatment (blue).

Fig 3